New Drug Approval: Suzetrigine (Journavx)

It’s been a while since we’ve written about a new drug approval, but when there’s a first-in-class, novel agent approved to target the opioid epidemic, that kinda gets a pharmacist’s attention. Wouldn’t you agree? Come learn about suzetrigine so that you can decide whether this analgesic may have a place in your therapy arsenal.

FDA Approval, Clinical, Pharmacy School, Practice, ResidencyStephanie KujawskiFebruary 10, 2025suzetrigine Journavx, non-opioid pain medication analgesia, selective sodium channel blocker for pain, opioid sparing pain medication regimens, how to treat acute pain without an opioid, new drug approval FDA 2025